Oric Pharmaceuticals
ORIC
164 hedge funds and large institutions have $979M invested in Oric Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 34 reducing their positions, and 21 closing their positions.
184% more call options, than puts
Call options by funds: $383K | Put options by funds: $135K
100% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 34
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
13.2% more ownership
Funds ownership: 109.65% → 122.84% (+13%)
8% more funds holding
Funds holding: 152 → 164 (+12)
23% less capital invested
Capital invested by funds: $1.28B → $979M (-$298M)
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$27.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$14.2M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$13.9M |
| 5 |
Goldman Sachs
New York
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.6M |
| 2 |
VA
VR Adviser
New York
|
-$10.6M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$9.58M |
| 4 |
JP Morgan Chase
New York
|
-$9.37M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.55M |
ORIC Hedge Fund Activity: Q4 2025 in Review
164 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q4 2025, worth a combined $979M — down 23% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ORIC positions and 21 closed out — a net gain of 13 holders — while 68 added to existing stakes and 34 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $27.6M. The largest seller was Vivo Capital, cutting an estimated $11.6M.
- 164 institutional investors held Oric Pharmaceuticals (ORIC) as of Q4 2025, up from 152 in Q3 2025.
- Funds reported $979M of Oric Pharmaceuticals stock for Q4 2025, down 23% quarter-over-quarter.
- 34 funds opened new Oric Pharmaceuticals positions in Q4 2025 and 21 closed out, a net change of +13 holders.
- The largest Oric Pharmaceuticals buyer in Q4 2025 was Paradigm Biocapital Advisors, an estimated $27.6M added.
- The largest Oric Pharmaceuticals seller in Q4 2025 was Vivo Capital, an estimated $11.6M sold.
Based on aggregated 13F filings for Q4 2025.